1. Subjects must provide informed consent prior to performance of study-specific<br/>             procedures or assessments, and must be willing to comply with treatment and<br/>             follow-up. Procedures conducted as part of the subject's routine clinical management<br/>             (e.g., blood count, imaging study) and obtained prior to signing of informed consent<br/>             may be utilized for screening or baseline purposes provided these procedures are<br/>             conducted as specified in the protocol<br/><br/>          2. Histologically or cytological confirmed uterine leiomyosarcoma or uterine<br/>             carcinosarcoma including any subtypes<br/><br/>          3. Patient must have received one or two prior chemotherapies<br/><br/>          4. For patients with prior anthracycline therapy normal cardiac function with LVEF at<br/>             least 50% must be assessed by quantitative echocardiogram or MUGA scan<br/><br/>          5. Prior Gemcitabine containing chemotherapy is permitted provided that at least 8 weeks<br/>             have elapsed since the last dose of therapy<br/><br/>          6. ECOG performance status 0-1<br/><br/>          7. At least 18 years old<br/><br/>          8. Measurable disease according to RECIST v 1.1 criteria (in case of tumour debulking -<br/>             staging CT-scan after surgery)<br/><br/>          9. Able to swallow and retain oral medication<br/><br/>         10. Adequate organ system function as defined in Table 1<br/><br/>             Table 1: Definitions for Adequate Organ Function System Laboratory Values Hematologic<br/>             Absolute neutrophil count (ANC) > =  1.5 X 109/L Hemoglobin1 > = 9 g/dL (5.6 mmol/L)<br/>             Platelets > = 100 X 109/L Prothrombin time (PT) or international normalized ratio<br/>             (INR)4  <= 1.2 X upper limit of normal (ULN) Partial thromboplastin time (PTT) <=1.2<br/>             X ULN Hepatic2 Total bilirubin <= 1.5 X ULN AST and ALT <= 2.5 X ULN Renal Serum<br/>             creatinine <= 1.5 mg/dL (133 µmol/L)<br/><br/>        Or, if greater than 1.5 mg/dL:<br/><br/>        Calculated creatinine clearance > = 50 mL/min<br/><br/>        Urine Protein to Creatinine Ratio (UPC)3 < 1<br/><br/>          1. Subjects may not have had a transfusion within 7 days prior to screening assessment.<br/><br/>          2. Concomitant elevations in bilirubin and AST/ALT above 1.0 x ULN are not permitted<br/><br/>          3. If UPC  > = 1, then a 24-hour urine protein must be assessed.  Subjects must have a<br/>             24-hour urine protein value <1g to be eligible.<br/><br/>          4. Subjects receiving anticoagulant therapy are eligible if their INR is stable and<br/>             within the recommended range for the desired level of anticoagulation<br/><br/>        11. Non-childbearing potential (i.e., physiologically incapable of becoming pregnant),<br/>        including any female who has had:<br/><br/>          -  A hysterectomy<br/><br/>          -  A bilateral oophorectomy (ovariectomy)<br/><br/>          -  A bilateral tubal ligation<br/><br/>          -  Is post-menopausal Subjects not using hormone replacement therapy (HRT) must have<br/>             experienced total cessation of menses for ≥ 1 year and be greater than 45 years in<br/>             age, OR, in questionable cases, have a follicle stimulating hormone (FSH) value >40<br/>             mIU/mL and an estradiol value < 40pg/mL (<140 pmol/L).<br/><br/>        Subjects using HRT must have experienced total cessation of menses for >= 1 year and be<br/>        greater than 45 years of age OR have had documented evidence of menopause based on FSH and<br/>        estradiol concentrations prior to initiation of HRT<br/><br/>        OR<br/><br/>        Negative serum pregnancy test of women of childbearing potential performed within 1 week<br/>        prior to the first dose of study treatment, preferably as close to the first dose as<br/>        possible, and agrees to use adequate contraception. Acceptable contraceptive methods, when<br/>        used consistently and in accordance with the product label and the instructions of the<br/>        physicians are as followed for 14 days before exposure to investigational product, through<br/>        the dosing period and for at least 21 days after the last dose of investigational product:<br/><br/>          -  Complete abstinence from sexual intercourse<br/><br/>          -  Oral contraceptive, either combined or progestogen alone<br/><br/>          -  Injectable progestogen<br/><br/>          -  Implants of levonorgestrel<br/><br/>          -  Estrogenic vaginal ring<br/><br/>          -  Percutaneous contraceptive patches<br/><br/>          -  Intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate<br/>             of less than 1% per year<br/><br/>          -  Male partner sterilization (vasectomy with documentation of azoospermia) prior to the<br/>             female subject's entry into the study, and this male is the sole partner for that<br/>             subject<br/><br/>          -  Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps)<br/>             with a vaginal spermicidal agent (foam/gel/film/cream/suppository) Female subjects<br/>             who are lactating should discontinue nursing prior to the first dose of study drug<br/>             and should refrain from nursing throughout the treatment period and for 14 days<br/>             following the last dose of study drug.<br/>